IKNA NASDAQ
Ikena Oncology, Inc.
1W: +12.6%
1M: +6.7%
3M: +18.2%
1Y: -14.9%
3Y: -74.0%
$17.16
Last traded 2025-07-25 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$718.8M
52W Range1.36-23.28
Volume457,262
Avg Volume18,002
Beta0.50
Dividend—
Analyst Ratings
Company Info
CEOMark Manfredi
Employees10
SectorHealthcare
IndustryBiotechnology
IPO Date2021-03-26
Websiteikenaoncology.com
645 Summer Street
Boston, MA 02210
US
Boston, MA 02210
US
857 273 8343
About Ikena Oncology, Inc.
Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Latest News
No recent news
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC | A-Award | 153,121 | — | 2023-08-04 |
| ORBIMED ADVISORS LLC | A-Award | 353,192 | — | 2023-08-04 |
| Bonita David P | A-Award | 153,121 | — | 2023-08-04 |
| Bonita David P | A-Award | 353,192 | — | 2023-08-04 |
| Koehler Maria | A-Award | 26,838 | $18.45 | 2021-04-15 |